Somatic G17V RHOA mutations were found in 50-70% of angioimmunoblastic T-cell lymphoma (AITL). The mutant RHOA lacks GTP binding capacity, suggesting defects in the classical RHOA signaling. Here, we discovered the novel function of the G17V RHOA: VAV1 was identified as a G17V RHOA-specific binding partner via high-throughput screening. We found that binding of G17V RHOA to VAV1 augmented its adaptor function through phosphorylation of 174Tyr, resulting in acceleration of T-cell receptor (TCR) signaling. Enrichment of cytokine and chemokine-related pathways was also evident by the expression of G17V RHOA. We further identified VAV1 mutations and a new translocation, VAV1-STAP2, in seven of the 85 RHOA mutation-negative samples (8.2%), whereas none of the 41 RHOA mutation-positive samples exhibited VAV1 mutations. Augmentation of 174Tyr phosphorylation was also demonstrated in VAV1-STAP2. Dasatinib, a multikinase inhibitor, efficiently blocked the accelerated VAV1 phosphorylation and the associating TCR signaling by both G17V RHOA and VAV1-STAP2 expression. Phospho-VAV1 staining was demonstrated in the clinical specimens harboring G17V RHOA and VAV1 mutations at a higher frequency than those without. Our findings indicate that the G17V RHOA-VAV1 axis may provide a new therapeutic target in AITL.
INTRODUCTION
Angioimmunoblastic T-cell lymphoma (AITL) is a subtype of peripheral T-cell lymphoma. 1 AITL patients display generalized lymphadenopathy and immune system-mediated manifestations including high fever, skin rash, polyarthritis, hemolytic anemia and hypergammaglobulinemia. 2 We and others previously conducted gene mutational profiling of AITL samples and observed RHOA mutations converting glycine to valine at amino acid 17 (the G17V RHOA mutation) in up to 70% of AITL. [3] [4] [5] Genes encoding the epigenetic regulators TET2, DNMT3A and IDH2 are also frequently mutated in AITL. 3, 4, [6] [7] [8] [9] [10] RHOA is a small GTPase that cycles between guanosine diphosphate (GDP)-bound inactive and guanosine-triphosphate (GTP)-bound active forms. Guanine nucleotide exchange factors (GEFs) activate RHOA by replacing GDP with GTP. Physiologically, RHOA mediates migration and polarity of T cells. 11, 12 RHOA also functions in thymocyte development 13, 14 and activation of pre-Tcell receptor (pre-TCR) signaling in thymocytes. 13, 15 Glycine at RHOA residue 17 is located at a critical position for GTP binding. G17V RHOA protein is considered to be a loss-of-function mutant, as G17V RHOA does not bind Rhotekin, a molecule with high affinity for the GTP-bound form. [3] [4] [5] Nonetheless, the impact of G17V RHOA expression on AITL remains unclear.
The VAV1 protein mediates a signaling cascade triggered by the TCR engagement partly through GEF activity, 16 whereas GEFindependent VAV1 functions are also reported. 17, 18 In the latter, VAV1 functions as an adaptor in a protein complex that promotes phosphorylation of phospholipase C-γ1 (PLCγ1). 18, 19 PLCγ1 phosphorylation induces its own enzymatic activity to upregulate the second messengers diacylglycerol and inositol 1,4,5-triphosphate, in turn promoting calcium-calmodulin signaling and enhancing nuclear factor of activated T cells (NFAT) transcription. 20 VAV1 also functions in extracellular signalregulated kinase, c-Jun N-terminal kinase and nuclear factor-κB pathways, 21 and its activation is tightly regulated by multilayered autoinhibition by interaction of its Dbl-homology (DH) domain with both acidic (167-178) 22 and C-terminal Src homology 2 (SH2)/SH3 domains. TCR engagement initially triggers the phosphorylation of Tyr142 and Tyr160 of VAV1 protein, destabilizing modulatory contacts and facilitating recruitment of the Src kinases LCK and FYN by providing a docking site for their SH2 domains. Thereafter, VAV1 Tyr174 is phosphorylated, 23 relieving core inhibitory interactions with the acidic and DH domains, resulting in the activation of downstream effectors. Conversion of Tyr174 to either Phe 17 or Asp 24 or physiologic phosphorylation of the wild-type Tyr174 residue reportedly activates VAV1 signaling. In addition, deletion of the VAV1 C terminus enhances its signaling. 25 Here we used mass spectrometry and immunoprecipitation to show that the G17V RHOA protein specifically binds to VAV1 protein. Upon TCR stimulation, VAV1 binding to G17V RHOA accelerated VAV1 phosphorylation and the eventual downstream signaling cascade.
MATERIALS AND METHODS

Patients and samples
Samples were obtained from patients with approval of local ethics committees in all participating institutes. Informed consent was obtained from all living subjects.
Cells
Jurkat cells inducibly expressing the wild-type (WT) and G17V RHOA mutant complementary DNA (cDNA) and mock-transduced cells have been previously described. 3 We newly established VAV1-STAP2-expressing Jurkat cells with a method similar to the previous one. 3 SU9T01 cells inducibly expressing WT or G17V RHOA cDNA and mock-transduced cells were also established previously.
Jurkat cells and SU9T01 cells were cultured at 37°C in RPMI-1640 Medium (Sigma-Aldrich, St Louis, MO, USA) supplemented with 10% fetal calf serum and 1% penicillin streptomycin. The 293T cells were cultured at 37°C in Dulbecco's modified Eagle's medium (Sigma-Aldrich) supplemented with 10% fetal calf serum and 1% penicillin streptomycin. Figure 1 . VAV1 activation by G17V RHOA in Jurkat cells. Jurkat mock , Jurkat WTRHOA and Jurkat G17V cells were stimulated for 5 or 30 min with or without anti-CD3 antibody, followed by anti-mouse IgG antibody. Immunoblots of lysates were performed with antibodies to VAV1, phospho VAV1 (Tyr174), PLCγ1 and phospho PLCγ1. β-Actin served as loading control. p-PLCγ1, phospho PLCγ1; p-VAV1, phospho VAV1. Figure 2 . Binding of SLP 76 and phosphorylated PLCγ1 as well as VAV1 and phospho VAV1 to G17V RHOA in Jurkat cells. Jurkat mock , Jurkat WTRHOA and Jurkat G17V cells were stimulated for 5 min with or without anti-CD3 antibody, followed by anti-mouse IgG antibody. Protein was immunoprecipitated from lysates using anti-Flag antibody and then immunoblotted with antibodies to Flag (RHOA), VAV1, phospho VAV1 (Tyr174), PLCγ1, phospho PLCγ1, and SLP76. β-Actin served as loading control. Asterisk (*) indicates G17V RHOA mutant. p-PLCγ1, phospho PLCγ1; p-VAV1, phospho VAV1.
Other experimental methods DNA extractions, targeted sequencing of RHOA, VAV1, PLCg1, CD28, FYN and LCK genes, antibodies, inhibitors, mRNA sequencing, plasmids, in vitro TCR stimulation, immunoprecipitation, mass spectrometry, NFAT reporter assay, interleukin-2 (IL-2) expression assay and immunohistochemistry are described in Supplementary Information.
RESULTS
Identification of G17V RHOA-specific binding proteins in Jurkat cells
To identify specific binding partners of G17V RHOA, we performed immunoprecipitation analysis in Jurkat cells overexpressing Flagtagged WT RHOA (Jurkat WTRHOA ) or the G17V RHOA mutant (Jurkat G17V ). Specifically, we used ANTI-FLAG Magnetic beads in either line, with or without TCR stimulation (Supplementary Figure 1 ). By targeted pull-down followed by mass spectrometry, we identified G17V RHOA-specific binding proteins: 44 proteins were identified specifically using G17V bait, both with and without TCR stimulation, 36 specifically without stimulation and 71 specifically with stimulation (Supplementary Table 1 , rows 54-56). The corresponding database search results for the 44-protein subset showed the highest Mascot scores to be attributable to VAV family proteins, namely VAV1 and VAV3 (Supplementary Table 2 , rows 77 and 78). Here, Mascot protein score is a surrogate for protein abundance. Notably, PLCγ1, an essential component of the TCR pathway, was detected among the G17V RHOA-specific binding proteins only with TCR stimulation (Supplementary Table 2 , row 105).
Both tumor-associated G17V 3-5 and engineered G17A RHOA mutants 26 lose nucleotide binding capacity, and both have been shown to tightly bind various GEFs. Notably, in COS7 cells the G17A RHOA mutant interacts with active VAV1 mutants that lack the inhibitory N-terminal regions (Δ1-186) or C-terminal SH3 domains (Δ835-845). 25 Here, we performed western blot and immunoprecipitation analysis using Jurkat WTRHOA and Jurkat G17V to validate mass spectrometry results reported above ( Supplementary Figure 2 ). VAV1 was specifically coprecipitated with the G17V RHOA mutant but not with wild-type RHOA in the presence or absence of TCR stimulation, but binding efficiency was markedly augmented by TCR stimulation (Supplementary Figure 2 ). The result was consistent with the elevated Mascot score by mass spectrometry (Supplementary Table 2 , row 78). In contrast, in similar assays we did not observe VAV3 binding to the G17V RHOA mutant (data not shown).
Various deletion mutants lacking the functional domains of VAV1 to determine the binding site for the G17V RHOA were made ( Supplementary Figure 7a) . A deletion mutant lacking the DH domain did not bind to the G17V RHOA, whereas other mutants as well as wild-type VAV1 did ( Supplementary Figure 7b) . These observations suggest that the DH domain is essential for binding to the G17V RHOA.
Interaction with G17V RHOA activates VAV1, enhancing its adaptor function As described, VAV1 phosphorylation at Tyr174 is critical for its activation following TCR stimulation. Remarkably, we detected VAV1 Tyr174 phosphorylation in Jurkat G17V cells, even in an unstimulated state, although at low levels, whereas Tyr174 phosphorylation was not seen in unstimulated Jurkat WTRHOA or mock-transduced cells (Figure 1 and Supplementary Figure 3 ). TCR stimulation enhanced VAV1 phosphorylation in both Jurkat WTRHOA Figure 3 . Effect of Src inhibitors on VAV1 activation by G17V RHOA following TCR stimulation. Jurkat mock , Jurkat WTRHOA and Jurkat G17V cells were stimulated with or without anti-CD3 antibody, followed by anti-mouse IgG antibody after (a) PP2 or (b) dasatinib treatment at indicated concentrations. Lysates were fractionated and immunoblotted with antibodies to VAV1, phospho VAV1 (Tyr174), PLCγ1 and phospho PLCγ1. β-Actin served as loading control. p-PLCγ1, phospho PLCγ1; p-VAV1, phospho VAV1. and mock cells, but that effect was more pronounced in Jurkat G17V cells (Figure 1 and Supplementary Figure 3 ). VAV1 mediates PLCγ1 phosphorylation through facilitating assembly of a PLCγ1-SLP76-LAT complex. 19 As anticipated, PLCγ1 phosphorylation was more striking in Jurkat G17V than in mock-transduced or Jurkat WTRHOA cells upon TCR stimulation (Figure 1 and Supplementary Figure 3 ). SLP76, an adaptor molecule, and phosphorylated PLCγ1 as well as total and phosphorylated VAV1 were also co-immunoprecipitated with G17V but not with wild-type RHOA (Figure 2 ). These observations suggest that G17V RHOA-VAV1 interaction enhanced the adaptor function of VAV1 to facilitate formation of a TCR signaling complex. Src kinases reportedly mediate TCR signaling-dependent VAV1 phosphorylation. PP2, a pan-Src inhibitor, dose-dependently inhibited VAV1 phosphorylation (Figure 3a ). In addition, some Src kinases including LCK and FYN are known targets of dasatinib, a drug used to treat BCR-ABL-positive leukemias. Thus, we asked whether dasatinib would inhibit VAV1 phosphorylation. As expected, dasatinib dose-dependently inhibited VAV1 phosphorylation, almost completely at 10 nM, in both Jurkat G7V and Jurkat WT cells (Figure 3b ). PLCγ1 phosphorylation was also inhibited by PP2 and more efficiently by dasatinib (Figures 3a and b) .
We also observed enhanced phosphorylation of VAV1 and PLCγ1 following induction of G17V RHOA expression in SU9T01 cells, an adult T-cell leukemia/lymphoma (ATLL) line, whereas induction of WT RHOA had no effect ( Supplementary  Figure 4 ). Furthermore, transient transduction of 293T cells with VAV1 cDNA plus either WT or G17V RHOA revealed greater VAV1 phosphorylation in the presence of G17V RHOA (Supplementary Figure 5 ). VAV1 and G17V RHOA also co-immunoprecipitated in 293T cells (Supplementary Figure 6) . These data overall suggest that VAV1 activation in the presence of the G17V RHOA mutant occurs in a variety of cell types.
Activating VAV1 mutations occur in human AITL and PTCL-NOS VAV1 translocations and missense/deletion mutations have been identified in T-cell lymphomas. [27] [28] [29] Here, RNA sequencing of 9 peripheral T-cell lymphoma (PTCL) samples (6 AITL Table 5 ). In total, seven VAV1 alterations including mutations of varying types and a fusion were found in 85 RHOA mutation-negative samples (8.2%), whereas none of the 41 RHOA mutation-positive PTCL samples exhibited VAV1 mutations (Figure 4d ). In addition, we examined mutations in PLCG1, CD28, FYN and LCK for 49 samples. Six PLCG1 mutations, two CD28 mutations and one FYN mutation were detected, whereas LCK mutations were not ( Supplementary Figure 8 ). Although the sample number was too small to elicit proper conclusion, both RHOA and VAV1 mutations were not exclusive with these mutations.
Analysis of Jurkat cells inducibly overexpressing VAV1-STAP2 (Jurkat VAV1-STAP2 ) showed robust phosphorylation of VAV1-STAP2 at Tyr174, even in TCR-unstimulated conditions (Figure 5a and Supplementary Figure 9 ). VAV1 phosphorylation was faintly detected in cells overexpressing WT VAV1 (Jurkat WTVAV1 ) but not in mock-transduced (Jurkat mock ) cells when the TCR was unstimulated (Figure 5a and Supplementary Figure 9 ). TCR stimulation enhanced phosphorylation of both VAV1-STAP2 and WT VAV1, but VAV1-STAP2 was more highly phosphorylated than WT VAV1 (Figure 5a and Supplementary Figure 9 ). Unlike G17V RHOA expression, VAV1-STAP2 expression enhanced PLCγ1 phosphorylation, even without TCR stimulation (Figure 5a ). These observations suggest that VAV1-STAP2 may autonomously activate TCR signaling without antigen stimulation. PLCγ1 phosphorylation was more striking in Jurkat VAV1-STAP2 than in mock-transduced or Jurkat WTVAV1 cells upon TCR stimulation. Phosphorylation of VAV1-STAP2 and WT VAV1 was dose-dependently inhibited by either PP2 or dasatinib treatment (Figures 5b and c) .
Enhanced NFAT activity upon TCR stimulation by G17V RHOA and VAV1 mutants NFAT transcription factors are essential for T-cell activation and differentiation, and TCR stimulation activates NFATs through Ca 2+ mobilization. 30 VAV1 mediates Ca 2+ mobilization mainly through PLCγ1 activation. 19 To identify potential function of G17V RHOA in NFAT activity, we transiently transfected Jurkat cells with a reporter vector containing an NFAT response element plus WT or G17V RHOA cDNAs in the presence or absence of TCR stimulation. Expression of G17V RHOA augmented NFAT activity upon TCR stimulation, whereas that of the WT construct did not (Figure 6a ). Dasatinib dose-dependently inhibited NFAT activity in Jurkat cells transduced with either WT or G17V RHOA (Figure 6b ).
We also assessed NFAT activity in Jurkat cells transiently transduced with the NFAT response element reporter plus WT VAV1 or VAV1-STAP2, VAV1 p.173_177del, p.165_174del and p. Pro615Leu mutant cDNAs with or without TCR stimulation. In unstimulated conditions, the VAV1-STAP2 construct promoted induced NFAT activity in Jurkat cells as the previously reported fusions, VAV1-MYO1F and VAV1-S100A7 29 did, whereas the other mutants and WT VAV1 did not ( Supplementary Figures 10a and Figure 5 . Effect of Src inhibitors on VAV1-STAP2 activation. (a-c) Jurkat mock , Jurkat WTVAV1 and Jurkat VAV1-STAP2 cells were stimulated with or without anti-CD3 antibody followed by anti-mouse IgG antibody. Cells were treated with (b) PP2 or (c) dasatinib at indicated concentrations. Lysates were fractionated and immunoblotted with antibodies to VAV1, phospho VAV1, and PLCγ1. β-Actin served as loading control. p-PLCγ1, phospho PLCγ1; p-VAV1, phospho VAV1.
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). Under TCR stimulation, NFAT activity was enhanced by transduction of WT VAV1 relative to mock control cells, whereas all VAV1 mutants had a greater enhancement effect than did WT VAV1 ( Supplementary Figure 10a) . Dasatinib treatment abrogated NFAT activity in Jurkat cells transduced with either WT or mutant VAV1 ( Supplementary Figure 10b) .
G17V RHOA and VAV1-STAP2 enhances IL-2 mRNA expression IL-2 is a pivotal NFAT target gene. 30 We observed increased IL-2 mRNA expression following TCR stimulation of Jurkat mock , peaking at 3 h and decreasing to slightly above basal levels by 6 h (Figure 6c ). Such TCR stimulation-dependent IL-2 expression was markedly enhanced by G17V RHOA, whereas WT RHOA rather repressed TCR stimulation-dependent IL-2 mRNA expression ( Figure 6c ). Dasatinib almost completely suppressed IL-2 mRNA induction by TCR stimulation in Jurkat G17V cells at doses that suppressed VAV1 phosphorylation (Figure 6d ).
We also examined IL-2 expression in Jurkat VAV1-STAP2 , Jurkat WTVAV1 and Jurkat mock cells in the presence or absence of TCR stimulation. IL-2 expression under TCR stimulation was higher in Jurkat VAV1-STAP2 than in Jurkat WTVAV1 or Jurkat mock control cells ( Supplementary Figure 12a) . IL-2 induction by TCR stimulation in Jurkat VAV1-STAP2 was dose-dependently inhibited by dasatinib treatment (Supplementary Figure 12b) .
Enrichment of cytokine-or chemokine-related signaling by G17V RHOA expression
We next performed mRNA sequencing analysis to examine effects of G17V RHOA on gene expression using RNA prepared from Jurkat cells inducibly expressing WT RHOA or G17V RHOA, or mock transduced, after CD3 and CD28 stimulation. Gene Set Enrichment Analysis demonstrated that cytokine-cytokine receptor interactions, chemokine signaling and TCR signaling pathways were significantly enriched at a false discovery rate q-value of o 0.25 for cells expressing WT RHOA or for mocktransduced cells (Figure 7 , Supplementary Figure 13 and Supplementary Table 6 ). AITL samples harboring RHOA or VAV1 mutations show enhanced VAV1 Tyr174 phosphorylation To determine whether VAV1 activation occurs in AITL tumor cells, we stained 26 human lymphoma samples using an antibody to VAV1 phosphorylated at Tyr174 (p-VAV1). In 12 AITL samples, all 8 samples with RHOA or VAV1 mutations were p-VAV1-positive, Table 7 ). Nine samples from patients with hematologic malignancies other than PTCL were negative for anti-p-VAV1 antibody. To determine the identities of anti-p-VAV1 antibody-positive cells, we performed double fluorescence staining in 11 PTCL samples exhibiting RHOA or VAV1 mutations. The p-VAV1-positive cells costained with antibody to programmed cell death 1 (PDCD1), a marker of AITL tumor cells in 9 of 11 PTCL samples with RHOA or VAV1 mutations (Figure 8 and Supplementary Table 7 ).
DISCUSSION
In AITL, the G17V RHOA mutation is among the most frequent gene alterations, whereas VAV1 mutations are seen at much lower frequencies. All of these alterations if examined activate VAV1 protein through promoting tyrosine phosphorylation and enhance TCR signaling. The G17V RHOA and VAV1 mutations were mutually exclusive in our cohort, though VAV1 fusions were examined only in a part of samples.
Nonetheless, the physiologic functions of RHOA are presumably abrogated in the G17V mutant, as the protein cannot be converted to the active GTP-bound form. VAV1 mediates TCR signaling as both a GEF to activate small GTPases and as an adaptor to facilitate formation or function of the TCR signaling complex. The results reported here strongly indicate that G17V RHOA modulates VAV1 function as an adaptor ( Supplementary  Figure 14) .
VAV1 mutations seen in AITL also enhance TCR signaling. Recent studies demonstrated that genes encoding members participating in TCR signaling are frequently mutated in AITL and related T-cell lymphomas. 28 Among genes encoding TCR signaling molecules, PLCG1 (14.1%), 28 CD28 (9.4-11.3%), 28, 31, 32 VAV1 (4.7%), 28, 29 and FYN (2.9-3.5%) 4,28 are most frequently mutated. ITK, 27, 33 VAV1 (refs. 27, 29) and CD28 (ref. 34) loci are also involved in recurrent chromosomal translocations. This evidence combined with our functional analysis of G17V RHOA suggest that enhanced TCR signaling induces development of T-cell neoplasms, comparable to the idea that enhanced BCR signaling due to mutations is a critical factor in development of B-cell neoplasms. 35, 36 In terms of gene expression, AITL tumor cells exhibit profiles comparable to follicular helper T cells, 2 and the transcription factors NFAT1 and NFAT2 are essential for follicular helper T-cell development. 37 Activation of NFAT by G17V RHOA may promote AITL tumor cell phenotypes. In addition, deregulated expression of ICOS, a signaling factor critical for follicular helper T-cell differentiation, 38 reportedly results in development of AITL-like disease in Roquin san heterozygous mice. 39 Several reports show that cyclosporine A, which blocks TCR signaling by inhibiting calcineurin, 40 is effective to treat some AITL patients. 41, 42 Dasatinib, which inhibits the tyrosine kinase ABL in BCR-ABL-positive chronic myelogenous leukemia and acute lymphoblastic leukemia, 43 also inhibits other cytoplasmic and receptor tyrosine kinases. 44 We found that aberrant VAV1 activation and subsequent signaling by G17V RHOA and VAV1 mutations are efficiently inhibited by dasatinib treatment. It is now important to conduct clinical studies to evaluate effects of dasatinib in AITL patients. G17V RHOA and VAV1 mutations were seen in AITL samples positive for phospho-VAV1 at a statistically higher frequency. Thus, detection of phospho-VAV1 by immunostaining may serve as a surrogate biomarker for dasatinib sensitivity.
Recent genetic studies identified RHOA mutations in lymphoid malignancies other than AITL, such as Burkitt's lymphoma 45 and ATLL, 46 as well as in diffuse-type gastric carcinoma, a nonhematologic malignancy. 47 These findings suggest that structural alteration of RHOA by mutation is a common mechanism underlying development of some malignancies. Mutational hot spots, however, differ among diseases: p.Arg5Gln and p.Tyr42Cys are most frequent in Burkitt's lymphoma 45 and gastric carcinomas, 47 whereas p.Cys16Arg is most frequent in ATLL. 46 Some RHOA mutants upregulate classical RHOA signaling whereas others downregulate it, even in a single disease. 46, 48 These outcomes are complex but possibly understandable if these RHOA mutants mediate oncogenesis through mechanisms other than modification of classical RHOA signaling as is shown here in AITL. VAV1 mutations are found in T-cell malignancies other than AITL, such as ATLL, 49 PTCL-NOS 27 and anaplastic large cell lymphoma, 27 as well as in nonhematologic cancers such as those of stomach, 47 pancreas 50 and melanoma. 50 Thus, RHOA and VAV1 mutations are frequent events in several cancers, although downstream mechanisms of these mutations in malignancies other than AITL remain to be elucidated.
In summary, our results demonstrate that the G17V RHOA-VAV1 axis is activated in AITL. This finding contributes to our understanding of AITL mechanisms and to efforts to develop targeted therapies. 
